Astrana Health (ASTH) Q4 2025 earnings review
Massive Scale Achieved Post-Acquisition, But Accounting Controls Falter
Astrana Health finished a transformative 2025 with $950.5 million in Q4 revenue (+43% YoY) and a 50% surge in Adjusted EBITDA to $52.5 million, fully reflecting the scale of the Prospect Health acquisition. The company is successfully executing its playbook, rapidly transitioning members into fully capitated risk arrangements and driving massive H2 growth. However, the record financial narrative is marred by a significant red flag: management is delaying its 10-K filing due to a material weakness in M&A accounting controls. Despite this administrative setback, 2026 guidance projects an accelerating 29% growth in Adjusted EBITDA, signaling that underlying operating leverage and deal synergies remain intact.
🐂 Bull Case
Guidance for Q1 2026 implies a 79% YoY jump in Adjusted EBITDA on 53% revenue growth, proving that the $12-$15 million in Prospect synergies are beginning to drop to the bottom line.
The company is successfully migrating acquired membership to full-risk contracts, projecting 80% of revenue to come from fully capitated arrangements by Q1 2026, which historically yields better margins as cohorts mature.
🐻 Bear Case
Filing a 12b-25 extension due to a material weakness in acquisition accounting is a major blow to credibility, especially for a company whose entire growth thesis relies on rolling up large, complex assets like CHS and Prospect.
Despite enterprise-wide growth, the physical Care Delivery segment posted a slight operating loss in Q4, raising questions about the profitability of its clinic footprint amidst rapid expansion.
⚖️ Verdict: 🟢
Bullish. The fundamental engine is performing exceptionally well, with Prospect integration driving significant scale and 2026 guidance indicating strong operational leverage. While the 10-K delay is a sharp negative, it appears to be a documentation issue rather than a structural flaw in the unit economics.
Key Themes
Prospect Integration Unlocking Operating Leverage
The integration of Prospect Health (closed Q3 2025) is tracking ahead of schedule. While Q4 Adjusted EBITDA of $52.5 million decelerated sequentially from Q3's $68.5 million (largely due to anticipated delays in contract transitions previously flagged by management), the Q1 2026 guidance calls for a sharp rebound to $60-$70 million. The company expects to hit the high end of its $12-$15 million synergy target.
Material Weakness Contradicts Smooth Integration Narrative
Management has repeatedly touted seamless M&A integration, yet the company announced a 15-day delay to its 2025 10-K due to a 'material weakness in internal control over financial reporting' directly linked to acquisition and purchase accounting. While management claims this won't result in restatements, this specific failure contradicts the polished narrative of their rapid roll-up strategy and introduces immediate governance risk.
Accelerating Shift to Full-Risk Arrangements
Astrana's core strategy of converting partial-risk to full-risk contracts is accelerating. Full-risk arrangements accounted for 68% of capitated revenue in 2024, grew to 76% in 2025, and are projected to reach 80% by Q1 2026. This deliberate transition locks in higher top-line revenue and aligns incentives to drive long-term profitability.
AI Platform Yielding Tangible Savings
Investments in Astrana's proprietary Care Enablement platform are paying off. The deployment of AI-enabled tools across clinical workflows, predictive modeling, and administrative processes directly contributed to a 75 bps decrease in G&A and a 110 bps decrease in Adjusted G&A year-over-year, proving the technology can successfully absorb the massive influx of Prospect's 600,000 members.
Medicaid Headwinds and Cost Trends
Macro regulatory dynamics, particularly procedural disenrollments and rate/acuity mismatches in the California Medicaid program, remain an ongoing pressure point. While management has historically managed medical cost trends below their 4.5% target, integrating Prospect's higher-trend business into this volatile macro environment limits near-term margin expansion in the Care Partners segment.
Care Delivery Segment Lags
While Care Partners and Care Enablement are thriving, the Care Delivery (clinic) segment struggled. Despite generating $92.1 million in Q4 revenue (+153% YoY), it posted an operating loss of roughly $36,000. Scaling physical clinics is proving significantly less efficient than scaling the digital and network segments.
Confidence Signaled Through Capital Returns
The Board doubled the share repurchase authorization from $50 million to $100 million. Given that the company repurchased 633,844 shares in Q4 alone, this indicates strong management conviction in cash flow generation and comfort with their pro-forma deleveraging timeline, even after the $708 million Prospect acquisition.
Other KPIs
Stable and accelerating. Up 38% YoY, this segment continues to be the dominant top-line engine, primarily driven by the ongoing conversion of the member base from partial-risk to fully capitated contracts.
Accelerating dramatically from $44.2 million in FY24. This 136% jump validates the cash-generative nature of Astrana's delegated model, even amidst high integration costs, giving the company ample flexibility to service its $1.04 billion in total debt.
General and administrative expenses housed in Corporate Costs remain elevated. This reflects the intense human capital and systemic investments required to integrate Prospect, restructure management, and (evidently) attempt to repair the internal controls that triggered the 10-K delay.
Guidance
Stable sequentially compared to 25Q4 ($950.5 million), but represents roughly 53% YoY growth at the midpoint compared to 25Q1. This reflects the full run-rate integration of Prospect Health.
Accelerating. The $65 million midpoint is a sharp 24% sequential increase from 25Q4's $52.5 million and a massive 79% YoY jump. This confirms management's prior statements that highly profitable full-risk contract transitions were delayed from late 2025 into Q1 2026.
Accelerating. Implies approximately 24% top-line growth over FY25's $3.18 billion, demonstrating organic traction on top of the inorganic base provided by Prospect.
Accelerating. Implies 29% YoY growth at the midpoint vs FY25's $205.4 million. Earnings are guided to grow faster than revenue, proving the margin expansion thesis of the Care Enablement platform and M&A synergy realization.
Key Questions
Depth of the Material Weakness
You cited a material weakness in 'acquisition and purchase accounting processes.' Is this isolated strictly to the Prospect Health integration, or does it cast a shadow backward onto the Collaborative Health Systems (CHS) acquisition as well?
Care Delivery Viability
The Care Delivery segment posted a slight operating loss in Q4 despite massive revenue growth. What is the path to profitability for physical clinics, and does this alter your appetite for owning brick-and-mortar assets versus pure tech enablement?
Medicaid Margin Trajectory
With 2026 guidance implying significant margin expansion, what assumptions have you baked in regarding California Medicaid rates and acuity mismatches, which were a stated headwind throughout 2025?